Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics has partnered with Regional Health Care Group, a Henry Schein company, to expand the distribution of its FebriDx® point-of-care diagnostic test in Australia and New Zealand, with immediate sales and marketing activities. FebriDx® enables rapid differentiation between viral and bacterial acute respiratory infections with results in just 10 minutes, improving patient management in various outpatient settings. This expansion is part of Lumos’s strategy to meet increasing demand for FebriDx, leveraging Henry Schein’s extensive distribution network.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
